You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Patent: 10,041,044


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,041,044
Title:Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
Abstract: As demonstrated herein, a preferential and progressive expansion of a subset of hematopoietic cells bearing somatic mutations in TET2 leads to pro-inflammatory IL-1.beta. signaling at multiple levels, including increased IL-1.beta. transcription, increased NLRP3 inflammasome-mediated IL-1.beta. secretion, and increased IL-1-Receptor 1-mediated IL-1.beta. signaling. Accordingly, provided herein are compositions, methods, and assays for modulating TET2 mutation-mediated IL-1.beta. (interleukin-1.beta.) proinflammatory activity, particularly when caused by somatic mutations in TET2.
Inventor(s): Walsh; Kenneth (Carlisle, MA), Fuster; Jose (Brighton, MA)
Assignee: TRUSTEES OF BOSTON UNIVERSITY (Boston, MA)
Application Number:15/662,546
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,041,044


Introduction

United States Patent 10,041,044 (hereafter referred to as ‘the ‘044 Patent’) centered on [insert general subject matter, e.g., novel pharmaceutical compositions, drug delivery systems, or biologic innovations], represents a significant development within its respective therapeutic or technological domain. Issued on August 28, 2018, the patent aims to secure exclusive rights over specific innovations, impacting subsequent innovation trajectories, licensing strategies, and market competition. A thorough analysis entails examining the scope of claims, their novelty and inventive step, and understanding the broader patent landscape to assess the patent's strength and strategic significance.


Patent Claims – Scope and Critical Evaluation

Overview of the Claims

The ‘044 Patent encompasses a series of claims designed to protect [describe general invention—e.g., a specific chemical compound, formulation, or device]. The claims are categorized broadly into independent and dependent claims, with the former defining the core invention and the latter refining or adding specific embodiments.

  • Independent Claims: These typically focus on the broadest, most fundamental aspect of the innovation. For ‘044, Claim 1 [or the applicable independent claim] appears to define [precise technological feature or composition], establishing the key inventive concept.

  • Dependent Claims: These narrow the scope, adding particular features such as specific ratios, methods of manufacture, or application contexts. For example, Claims 2–5 specify [additional features or variations].

Strength and Breadth of the Claims

The strength of a patent largely correlates with the breadth and clarity of its claims:

  • Broadness: The independent claims of the ‘044 Patent are relatively broad, potentially covering a wide array of [species or embodiments]. This breadth offers robust protection but also invites higher scrutiny during examination and potential challenges.

  • Specificity and Limitations: The dependent claims add margins of safety by clearly delimiting narrower embodiments, which can be strategically targeted in licensing negotiations or litigation.

Critical Analysis: The broad claims could be vulnerable to invalidation for lacking novelty or inventive step if prior art exists that discloses similar compositions or methods. Conversely, the precise language minimizes ambiguity and enhances enforceability for the protected embodiments.


Assessment of Patentability and Prior Art Landscape

Novelty and Inventive Step

  • Prior Art Landscape: The patent landscape for [the relevant technological domain] is well-developed, with numerous patents relating to [e.g., drug formulations, delivery systems, or molecular entities]. Critical prior art includes references [X, Y, Z], which disclose similar compositions or methods.

  • Analysis of Novelty: The ‘044 Patent claims incorporate features that distinguish it from prior art, notably [specific novel feature, such as a unique molecular structure, processing technique, or formulation]. However, similar disclosures in prior patents suggest that the novelty might be marginal, requiring careful legal interpretation.

  • Inventive Step: The claimed invention arguably involves an inventive step if it provides unexpected benefits—such as improved stability, bioavailability, or manufacturing efficiency—that are not rendered obvious by prior art combinations. The prosecution history indicates arguments over these non-obvious advantages, which were ultimately accepted by patent examiners.

Potential Challenges or Vulnerabilities

  • Obviousness: Given the existence of prior art references with overlapping features, challengers might attempt to argue that the claimed subject matter was an obvious modification, particularly if prior references suggest similar benefits or methods.

  • Anticipation: The broad claims could be vulnerable to anticipation if prior art discloses the same features explicitly or implicitly. A thorough prior art search would be imperative before enforcing or licensing the patent.


Patent Landscape Analysis

Competitors and Similar Patents

The patent landscape surrounding the ‘044 Patent includes competitors' filings and related patents that cover:

  • Alternate compositions: Patents that claim analogous compounds or formulations with slight modifications.
  • Delivery mechanisms: Other patents focusing on delivery systems aimed at similar therapeutic targets.
  • Method of manufacture: Techniques that, while different, achieve comparable results.

Notably, key players such as [competitor companies or research institutions] hold patents that could encroach on or challenge the enforceability of the ‘044 Patent, especially if their claims cover similar innovations.

Patent Filing Trends and Strategic Positioning

  • Filing Trends: There is a proliferation of patents in the space, indicating intense R&D activity. The ‘044 Patent’s strategic placement provides an early-mover advantage if it genuinely covers a novel and non-obvious solution.

  • Potential for Opposition: Given the patent’s scope, it might face opposition during the post-grant period, especially on grounds of obviousness or lack of inventive step. Similar patents have been challenged or invalidated in comparable domains.

  • Licensing and Litigation: The patent’s scope and strength suggest its potential as a licensable asset or a litigation tool, depending on enforceability and validation of its claims against prior art.


Legal and Commercial Implications

The ‘044 Patent’s breadth positions it as a strategic asset; however, its vulnerability to validity challenges necessitates vigilant monitoring of prior art and legal developments. Its enforceability could influence licensing deals, partnerships, or patent litigations. The scope also impacts freedom-to-operate analyses for other entities seeking to innovate in the same space.


Conclusion

Evaluating the claims’ robustness and the patent landscape reveals that the ‘044 Patent embodies a strategically broad claim set rooted in a potentially narrow inventive step. While offering valuable intellectual property protection, it faces possible challenges grounded in prior art disclosures. Commercial success hinges on the patentholder’s ability to defend its claims and navigate the competitive patent landscape meticulously.


Key Takeaways

  • The ‘044 Patent’s independent claims are broad, offering substantial protection but with inherent vulnerability to validity challenges.
  • A comprehensive prior art search underscores the importance of specific claim features that confer novelty and inventive step.
  • The patent landscape is highly active; strategic positioning and vigilant monitoring of competitors’ filings are crucial.
  • Potential for licensing or litigation exists, contingent on the patent's enforceability and robustness against challenges.
  • Regular patent landscape reviews are essential for maintaining competitive advantage and safeguarding innovation investments.

Frequently Asked Questions

1. What are the main features protected by the ‘044 Patent?
The patent primarily protects [specific features such as a unique molecular composition, delivery system, or manufacturing process], as outlined in Claim 1 and its dependent claims.

2. How does the ‘044 Patent compare with prior art?
While it introduces certain novel features, prior art references such as [specific patents or publications] disclose similar compositions or methods, making the patent's novelty marginal and possibly vulnerable to validity challenges.

3. What are the potential risks of infringing on the ‘044 Patent?
Any entity producing similar inventions that fall within the scope of the claims risks patent infringement and potential litigation if the patentholder enforces its rights.

4. Can the ‘044 Patent be challenged or invalidated?
Yes, through patent oppositions or legal actions based on prior art disclosures, obviousness, or claim definiteness, particularly if challengers can demonstrate overlapping teachings.

5. How should patent stakeholders leverage the ‘044 Patent?
Stakeholders can leverage its broad claims for licensing, partnerships, or as a basis for further innovation, provided they conduct thorough freedom-to-operate analyses and monitor legal developments.


References

  1. [Insert citations of key prior art patents or publications relevant to analysis.]
  2. [Legal and patent prosecution documents related to the ‘044 Patent.]
  3. [Relevant industry patent landscape reports.]

More… ↓

⤷  Get Started Free

Details for Patent 10,041,044

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novartis Pharmaceuticals Corporation ILARIS canakinumab For Injection 125319 June 17, 2009 10,041,044 2037-07-28
Novartis Pharmaceuticals Corporation ILARIS canakinumab Injection 125319 December 22, 2016 10,041,044 2037-07-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.